147 related articles for article (PubMed ID: 12498018)
1. FR-901228 Fujisawa/National Cancer Institute.
Vigushin DM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1396-402. PubMed ID: 12498018
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
Richon VM; O'Brien JP
Clin Cancer Res; 2002 Mar; 8(3):662-4. PubMed ID: 11895892
[No Abstract] [Full Text] [Related]
3. Aplidin PharmaMar.
Yao L
IDrugs; 2003 Mar; 6(3):246-50. PubMed ID: 12789614
[TBL] [Abstract][Full Text] [Related]
4. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
Yurek-George A; Cecil AR; Mo AH; Wen S; Rogers H; Habens F; Maeda S; Yoshida M; Packham G; Ganesan A
J Med Chem; 2007 Nov; 50(23):5720-6. PubMed ID: 17958342
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
6. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
7. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
8. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
9. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Ueda T; Takai N; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2007 Feb; 19(2):301-8. PubMed ID: 17203205
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors.
Kelly WK
Clin Adv Hematol Oncol; 2004 Nov; 2(11):722-3. PubMed ID: 16163258
[No Abstract] [Full Text] [Related]
11. Design and synthesis of a potent histone deacetylase inhibitor.
Liu T; Kapustin G; Etzkorn FA
J Med Chem; 2007 May; 50(9):2003-6. PubMed ID: 17419603
[TBL] [Abstract][Full Text] [Related]
12. Adaptive trials receive boost.
Jones D
Nat Rev Drug Discov; 2010 May; 9(5):345-8. PubMed ID: 20414200
[No Abstract] [Full Text] [Related]
13. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
14. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute.
Sheikh N
Curr Opin Mol Ther; 2003 Aug; 5(4):428-32. PubMed ID: 14513687
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
16. Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Kelland L
Curr Opin Mol Ther; 2007 Feb; 9(1):86-91. PubMed ID: 17330406
[TBL] [Abstract][Full Text] [Related]
17. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma.
Khan SB; Maududi T; Barton K; Ayers J; Alkan S
Br J Haematol; 2004 Apr; 125(2):156-61. PubMed ID: 15059137
[TBL] [Abstract][Full Text] [Related]
18. Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/ TRICARE; coverage of phase II and phase III clinical trials sponsored by the National Institutes of Health National Cancer Institute. Final rule.
Office of the Secretary, DoD
Fed Regist; 2006 Jun; 71(118):35389-91. PubMed ID: 16795948
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin.
De Schepper S; Bruwiere H; Verhulst T; Steller U; Andries L; Wouters W; Janicot M; Arts J; Van Heusden J
J Pharmacol Exp Ther; 2003 Feb; 304(2):881-8. PubMed ID: 12538846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
